Article: Commerzbank cuts German Gerresheimer to "hold".

Article: Commerzbank ups German Morphosys to "buy".
ADP News Germany;  September 8, 2009 ;     700 words ... ... share price target was lifted to EUR 18.40 from EUR 17.60. Despite the good performance ... have fallen recently, analyst Daniel Wendorff said. Good news is expected from ... Morphosys had jumped by 7.38% to EUR 16.58 on the floor of the Frankfurt ...

Article: Commerzbank lifts German Stratec Biomedical to "buy".
ADP News Germany;  December 11, 2009 ;     532 words ... ... reduce" and upped its share price target to EUR 31 from EUR 20 on Friday. Analyst Daniel Wendorff increased his forecast for the firm's revenue ... next six months. Stratec Biomedical closed at EUR 26.82, up by 3.67%, on Xetra on Friday ...

Article: Serono ends bid to attract a buyerMARKETPLACE by Bloomberg
International Herald Tribune;  April 11, 2006 ;     608 words ... ... according to Bank Sarasin in Zurich. Other possible acquisition targets could include Altana and Merck, according to Daniel Wendorff, an analyst at WestLB Equity Markets in Dusseldorf. Merck bid to buy another pharmaceutical company, Schering, but was ...

Article: Germany : Vossloh lower, major order cancelled.
TendersInfo;  October 9, 2009 ;     379 words ... ... additional order in a high double-digit million euro amount, for the Beijing-Wuhan railway," says Commerzbank analyst Daniel Wendorff. " "Vossloh confirmed that this order was awarded to local Chinese competition," Wendorff, who cuts the stock's target ...

Article: EGM rejects director.(extraordinary general meeting)(Robert ...
Chemistry and Industry;  March 20, 2006 ;     700+ words ... ... Venture, called the EGM, hoping to replace Jerry Karabelas with Thian, chair of UK drug-technology company Whatman. Daniel Wendorff, West LB analyst, said the close call was an indication that many shareholders are unhappy with the bad share-price ...

Article: GPC Biotech Shares Jump On Prostate Cancer Study Results.
BIOWORLD Today;  November 3, 2009 ;     700+ words ... ... president for strategic clinical affairs at GPC. "It is an extremely valuable and important part of the overall trial." Daniel Wendorff, analyst at WestLB AG in Dusseldorf, Germany, said the data were "a home run," and added that the study is "definitely ...

Article: SkyePharma chair goes.(Ian GowrieSmith resigns)(Brief article)
Chemistry and Industry;  February 6, 2006 ;     700+ words ... ... without risking bankruptcy and could, most probably, strike a better deal with phase III data in hand, said West LB analyst Daniel Wendorff. But, because the market has been expecting it for two years, a deal right now would be positive for shares. 'For short ...